Navigation Links
CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies

advantages, the relatively large therapeutic window could dramatically simplify patient enrollment compared with other stroke studies, which will allow us to conduct relatively cost-effective clinical trials in relatively short timeframes. We have begun developing a potential Phase II clinical plan for arimoclomol in stroke recovery."

About Stroke

According to the American Heart Association, every 45 seconds on average someone in the United States has a stroke, and every three minutes someone dies of stroke. Stroke is the third leading cause of death in the U.S. and accounts for more than 162,000 deaths in the U.S. each year. Of those people who survive a first stroke, 14% will have another one within a year. Stroke is the number one cause of long-term disability among Americans. Between 50% and 70% of stroke survivors regain functional independence; however 15% to 30% are permanently disabled. Three months after stroke, 20% of survivors require institutional care. According to the American Heart Association, stroke cost was approximately $58 billion in both direct and indirect costs in 2006.

About Arimoclomol

Arimoclomol is one of three CytRx-owned clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. Arimoclomol is believed to function by stimulating a normal cellular protein repair pathway through the activation of "molecular chaperones." Since damaged proteins called aggregates are thought to play a role in many diseases, CytRx believes that activation of molecular chaperones could have therapeutic efficacy for a broad range of diseases.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
3. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:9/2/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a ... chronic pain, announced today that the company,s management will ... Annual Healthcare Conference and BioCentury NewsMakers Conference.  Details of ... Annual Healthcare Conference Date:  Wednesday, September 9 ... No presentation, investor meetings only BioCentury NewsMakers ...
(Date:9/2/2015)... 2015 Tumultuous market conditions – including changes ... M&A activity – have led more than half of ... sales reps. This marks the first time that the ... halfway point, according to the spring 2015 AccessMonitor™ ... ZS . AccessMonitor™ aggregates sales-call ...
(Date:9/2/2015)... VANCOUVER, British Columbia and ...   DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on the development and commercialization of new cancer ... abstract entitled, "A Comparison of the Mechanisms ... in Ovarian Tumor Models Harboring Wild-type and Mutant ...
Breaking Medicine Technology:Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4
... According to the American,Academy of Dermatology (AAD), ... an inflamed skin condition characterized by red, scaly,and ... which tend to,flare up in the winter months, ... Eczema Care Moisturizing Cream and Body Wash, formulated,with ...
... Infection Control, WASHINGTON, Jan. 10 To ... minimize risks during times,of health crisis, DuPont (NYSE: ... its,healthcare products, DuPont(TM) Corian(R) solid surface, has been ... department. The product,recently was incorporated into a children,s ...
Cached Medicine Technology:New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4
(Date:9/2/2015)... Las Vegas, NV (PRWEB) , ... September 02, ... ... Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as an ... largest medical auction house in the world, selling more than 100,000 pieces of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 2015 , ... Please join the world renowned Brain Aneurysm ... established by the Foundation in 2007 with the help of Massachusetts State Representative ... remains our top priority,” commented Christine Buckley, Executive Director of the Brain Aneurysm ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of Breast Cancer Awareness Month (BCAM), Bright Pink, a national non-profit focused on ... will launch Act On Facts, a campaign to educate women to be breast ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 ... of plastic surgeries conducted each year on teenagers, quoting a New York City-area ... Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2
... January 12, 2010 (BRONX, NY) Older women ... lesions that cause dementia later in life, according to ... The findings were published in the December 2009 online ... The research was conducted as part of the ...
... WINSTON-SALEM, N.C. A fast-acting compound that appears to ... found in patients with progressive Alzheimer,s disease has been ... Medicine and the Vanderbilt University Medical Center Program in ... result in humans. The compound benzylquinolone carboxylic ...
... ... Molecular Medicine. Molecular Medicine publishes research concerned with the pathogenesis of disease at the ... prevention. , ... January 12, 2010 -- By the time a person experiences symptoms of an aggressive ...
... , DETROIT , Jan. 12 ... Board of Directors has set the date for the Company,s Annual Meeting ... vote at the meeting.   , The Annual Shareholders, Meeting will be ... EST at the MGM Grand Hotel, 1777 Third Street in ...
... hospice and preferred place of death are often needed, experts ... patients have much to consider, from whether they want to ... want doctors to continue aggressive treatment or focus on making ... those difficult, emotional conversations aren,t happening nearly as often, or ...
... WASHINGTON , Jan. 12 The American Lung ... report, which grades the strength of federal and state ... at the heart of America,s chronic disease crisis. , The ... still has significant room for progress. Most state governments , ...
Cached Medicine News:Health News:Hypertension linked to dementia in older women 2Health News:Hypertension linked to dementia in older women 3Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 2Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 3Health News:News from the Latest Issue of Molecular Medicine 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 3Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 2Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 2Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 4Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 5Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 6Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 7Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 8
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
... Evolve™ modular radial head system employs the ... research to create the next generation of ... two part, modular design, the implant system ... match the patients anatomy. In addition, the ...
For connection to the bipolar output of electrosurgical generators....
Recommended for use with spark gap coagulators for added safety. Also available in stainless steel (10-3002)....
Medicine Products: